如何治疗费城染色体阴性骨髓增殖性肿瘤的原始细胞期
本文为基于病例的综述,聚焦费城染色体阴性骨髓增殖性肿瘤原始细胞期(MPN-BP)的分子与临床异质性,指出有效治疗选择有限,异基因干细胞移植是唯一已知治愈手段,并整合了一套强调个体化治疗的治疗算法。
要点
- 费城染色体阴性MPN-BP的有效治疗选择有限。
- 异基因干细胞移植是唯一已知的治愈手段。
- 治疗应基于分子与临床异质性采取个体化策略。
核心结论
- MPN-BP的治疗进展将取决于前瞻性临床与转化研究,以产生更有效的治疗干预。
研究设计与样本
- 基于病例的综述,整合分子与临床异质性并提出治疗算法。
主要发现
- 经典费城染色体阴性MPN为异质性造血干细胞疾病,以JAK/STAT信号激活和显著表型拟态为特征,包括易演变为髓系原始细胞期疾病。
- 对分子发病机制的理解加深及靶向药物可及性增加,有望指导新的亚群特异性治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The classic Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem-cell diseases, characterized by activated JAK/STAT signaling and significant phenotypic mimicry, including a propensity for evolution to myeloid blast phase disease. Effective therapeutic options are limited for patients with Ph- MPNs in the blast phase (MPN-BP), and allogeneic stem-cell transplantation is the only known cure. Our increasing understanding of the molecular pathogenesis of this group of diseases, coupled with the increasing availability of targeted agents, has the potential to inform new subset-specific therapeutic approaches. Ultimately, progress in MPN-BP will hinge on prospective clinical and translational investigations with the goal of generating more effective treatment interventions. This case-based review highlights the molecular and clinical heterogeneities of MPN-BP and incorporates a treatment algorithm that underscores the importance of a personalized approach to this challenging group of diseases.
引用
- Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018. PMID: 30333119. doi:10.1182/blood-2018-03-785907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。